Revlimid and Bronchiolitis - a phase IV clinical study of FDA data

Summary:

Bronchiolitis is reported as a side effect among people who take Revlimid (lenalidomide), especially for people who are male, 60+ old, have been taking the drug for 1 - 6 months also take Zometa, and have Bone loss.

The phase IV clinical study analyzes which people have Bronchiolitis when taking Revlimid. It is created by eHealthMe based on reports of 377,717 people who have side effects when taking Revlimid from the FDA, and is updated regularly.

What is Revlimid?

Revlimid has active ingredients of lenalidomide. It is often used in multiple myeloma. eHealthMe is studying from 378,026 Revlimid users. Check the latest studies of Revlimid.

What is Bronchiolitis?

Bronchiolitis (inflammation of the membranes lining the bronchioles in lungs) is found to be associated with 406 drugs and 480 conditions by eHealthMe. Check the latest studies of Bronchiolitis.

On Aug, 02, 2026

377,717 people reported to have side effects when taking Revlimid.
Among them, 38 people (0.01%) have Bronchiolitis.

Among these 38 people:

How long have people been on Revlimid when they have Bronchiolitis? *

What is the gender of people who have Bronchiolitis when taking Revlimid? *

female: 50 %
male: 50 %

What is the age of people who have Bronchiolitis when taking Revlimid? *

What are other drugs people take besides Revlimid? *

What are other side effects people have besides Bronchiolitis? *

Thrombocytopenia (decrease of platelets in blood): 19 people, 50.00%
Pneumonia: 18 people, 47.37%
Dyspnea (difficult or laboured breathing): 17 people, 44.74%
Sepsis (a severe blood infection that can lead to organ failure and death): 16 people, 42.11%
Pleural Effusion (water on the lungs): 16 people, 42.11%
Chronic Obstructive Pulmonary Disease (a progressive disease that makes it hard to breathe): 16 people, 42.11%
Gallstones (stone formation by bile component): 15 people, 39.47%
Eyes - Bulging (swelling of eyes): 15 people, 39.47%
Fainting (loss of consciousness and postural tone): 15 people, 39.47%
Fall: 15 people, 39.47%

What are the existing conditions these people have? *

Neoplasm Malignant (cancer tumour): 15 people, 39.47%
Bone Loss: 15 people, 39.47%
Osteoporosis (bones weak and more likely to break): 8 people, 21.05%
Broken Bone: 8 people, 21.05%
Stress And Anxiety: 2 people, 5.26%
Neuropathy Peripheral (surface nerve damage): 2 people, 5.26%
Hypokalemia (low potassium): 2 people, 5.26%
Depression: 1 person, 2.63%
Atrial Fibrillation/flutter (atrial fibrillation and flutter are abnormal heart rhythms in which the atria, or upper chambers of the heart, are out of sync with the ventricles): 1 person, 2.63%
Bipolar Disorder (mood disorder): 1 person, 2.63%

* Approximation only. Some reports may have incomplete information.

Do you take Revlimid and have Bronchiolitis?

- Check whether Bronchiolitis is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Revlimid:

Revlimid (378,026 reports)

Bronchiolitis treatments and more:

Bronchiolitis (5,841 reports)

Browse all side effects of Revlimid:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Bronchiolitis:

Bronchiolitis (406 drugs)

Browse all the conditions that are associated with Bronchiolitis:

Bronchiolitis (480 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on lenalidomide (the active ingredients of Revlimid) and Revlimid (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.